Here's What Analysts Are Saying About Tenet Healthcare Corporation (THC) Post Earnings

Tenet Healthcare Corporation (NYSE:THC) is one of the best strong buy healthcare stocks to invest in. Truist lifted the price target on Tenet Healthcare Corporation (NYSE:THC) to $270 from $240 on February 17 and maintained a Buy rating on the shares, telling investors that it adjusted its model after the company released its fiscal Q4 financial results and 2026 guidance.

Wells Fargo also lifted the price target on Tenet Healthcare Corporation (NYSE:THC) to $265 from $229 on February 16, maintaining an Overweight rating on the shares. It stated in a post Q4 note that while the magnitude of the stock move on already previewed EBITDA and in-line guidance was “surprising,” strong capital return potential and alignment with key market narratives “appear to be important drivers.”

Tenet Healthcare Corporation (NYSE:THC) released its fiscal Q4 and full-year 2025 earnings on February 11, reporting that the net income available to common shareholders in fiscal Q4 was $371 million, or $4.22 per diluted share. Adjusted diluted earnings per share for the quarter rose 36.6% to $4.70 compared to $3.44 in the previous year period.

Tenet Healthcare Corporation (NYSE:THC) provides healthcare services, with its operations divided into the Hospital Operations and Ambulatory Care segments.

While we acknowledge the potential of THC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.